Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual MeetingGlobeNewsWire • 04/27/21
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare DiseasesBusiness Wire • 04/05/21
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenGlobeNewsWire • 02/17/21
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/12/21
Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate UpdateGlobeNewsWire • 02/11/21
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate UpdateGlobeNewsWire • 02/04/21
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson DiseaseGlobeNewsWire • 01/21/21
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy StudiesGlobeNewsWire • 01/08/21
Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare ConferenceGlobeNewsWire • 01/05/21
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis ImperfectaGlobeNewsWire • 12/17/20